Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SCN4A | P35499 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070752 | 1.00 | HSD17B10 (0.61) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL5423413 | 1.00 | HSD17B10 (0.61) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL13804206 | 0.95 | HSD17B10 (0.56) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL12427648 | 0.95 | HSD17B10 (0.56) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL13804123 | 0.95 | HSD17B10 (0.56) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL31048407 | 0.93 | HSD17B10 (0.55) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL7286305 | 0.90 | HSD17B10 (0.61) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL19414808 | 0.90 | HSD17B10 (0.61) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL895773 | 0.90 | HSD17B10 (0.61) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL14000638 | 0.89 | HSD17B10 (0.49) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705308-A1 | EGFR INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4536224-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | Blossomhill Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-107949384-B | Muscarinic agonists | 奈克斯拉制药英国有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119421709-A | Indazole-containing macrocyclic compounds and uses thereof | 荣山医药股份有限公司 | 2025-02-11 | — | — | CN | disclosed |
| WO-2024229091-A1 | EGFR INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024229087-A1 | EGFR INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| US-20240254136-A1 | COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS | Redona Therapeutics, Inc. | 2024-08-01 | — | — | US | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-112812128-B | Macrocyclic compounds as ALK and ROS modulators | 正大天晴药业集团股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-9115096-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| US-20070276017-A1 | Thiadiazoline Derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ABL1, EGFR | HSD17B10 4096/4885NPC1 3709/4885SMN1; SMN2 4263/4885 |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | HSD17B10 2037/4885NPC1 218/4885SMN1; SMN2 4709/4885 |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | HSD17B10 2037/4885NPC1 218/4885SMN1; SMN2 4709/4885 |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | HSD17B10 2499/4885NPC1 414/4885SMN1; SMN2 4705/4885 |
| US-20070276017-A1 | Thiadiazoline Derivative | BRD7, NR3C2, NR5A2 | HSD17B10 903/4885NPC1 3452/4885SMN1; SMN2 4003/4885 |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | AADAC, PAICS, CYP3A43 | HSD17B10 1926/4885NPC1 55/4885SMN1; SMN2 2592/4885 |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | HSD17B10 2499/4885NPC1 414/4885SMN1; SMN2 4705/4885 |
| US-20240254136-A1 | COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS | NSUN3, NSUN2, RBM3 | HSD17B10 3814/4885NPC1 833/4885SMN1; SMN2 952/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | HSD17B10 1951/4885NPC1 1263/4885SMN1; SMN2 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.